HEALTHEQUITY, INC. 8-K

What Happened
HealthEquity announced on April 6, 2026 that Chief Technology Officer Eli Rosner’s employment will be terminated by the company without cause, effective April 17, 2026. Sunil Rajasekar, the company’s Executive Vice President, Chief Product and Strategy Officer (who joined HealthEquity in January 2026), will be responsible for overseeing the company’s technology organization as of that date. The company said Rosner will receive previously negotiated severance payments and benefits subject to execution and non-revocation of a release of claims and continued compliance with certain restrictive covenants.

Key Details

• Termination announced April 6, 2026; effective April 17, 2026 (Eli Rosner, CTO).
• Interim oversight: Sunil Rajasekar (Executive VP, Chief Product & Strategy Officer) to oversee technology organization as of April 17, 2026. Rajasekar served as CEO of Billtrust (Nov 2022–Aug 2025) and President of MINDBODY (Sep 2018–Aug 2022).
• Severance: Rosner will receive the severance payments and benefits set forth in his employment agreement contingent on signing a release and complying with restrictive covenants; details referenced in HealthEquity’s proxy statement filed May 13, 2025.
• Equity treatment: Rosner’s outstanding equity awards will be handled in accordance with the 2014 Stock Incentive Plan, the 2024 Stock Incentive Plan, and applicable award agreements.

Why It Matters
This filing documents a leadership change in HealthEquity’s technology organization and the company’s plan for interim oversight, which is relevant for investors tracking executive stability and management structure. The filing also confirms severance and equity-treatment commitments (per existing agreements and plans); the company did not disclose dollar amounts in this 8‑K. Investors may look for any future disclosures that quantify severance costs or outline a permanent technology head appointment.